Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertensionheart failure and percutenous coronary interventions (PCI).

The new generation Abbott TriClip G4 device has gained European and Canadian approvals for transcatheter tricuspid valve repair (TTVR).

The new generation Abbott TriClip G4 device has gained European and Canadian approvals for transcatheter tricuspid valve repair (TTVR). The device is an iteration of the successful MitraClip device used for transcatheter mitral valve repairs. 

News | Structural Heart | April 08, 2021
April 8, 2021 — Abbott today announced it has received European CE mark and Health Canada authorization this week for...
A reconstructed vessel segment from a cone-beam CT created table side in the cath lab with the Philips Azurion SmartCT software.

A reconstructed vessel segment from a cone-beam CT created table side in the cath lab with the Philips Azurion SmartCT software. 

News | Angiography | April 07, 2021
April 7, 2021 — Philips Healthcare announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Philips...
Rapid Medical's TigerTrieve stent-retriever neuro thrombectomy system.

Rapid Medical's TigerTrieve stent-retriever neuro thrombectomy system.

News | Stroke | April 07, 2021
April 7, 2021 — Market research firm GlobalData's new report, Neurovascular Thrombectomy Devices (Neurology Devices),...
Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2] 

Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2] 

News | Stents | April 06, 2021
April 6, 2021 — Abbott today announced its Xience stent has received CE mark in Europe for shorter duration of dual...
Videos | Cath Lab | April 02, 2021
Corindus, a Siemens Healthineers company and a developer of vascular robotics, recently launched a new set of automated...
Videos | Coronavirus (COVID-19) | April 01, 2021
Behnood Bikdeli M.D., a cardiologist at the Brigham and Women’s Hospital, Harvard Medical School, Boston, offers an...
Sponsored Content | Case Study | Cardiovascular Information Systems (CVIS) | April 01, 2021
Washington Health System (WHS) provides healthcare services at more than 40 offsite locations across three counties in...
Videos | Cath Lab | March 31, 2021
This is a quick example of clinical use of the Shockwave Medical Intravascular Lithotripsy system that uses sonic wave...
Driven by pandemic realities and clinical demand for portable and intelligent point-of-care ultrasound (POCUS), GE Healthcare unveiled Venue Fit, a streamlined and compact POCUS system, alongside an industry-first artificial intelligence (AI) offering for cardiac imaging on the Venue and Venue Go. The Venue Fit is the smallest system in GE Healthcare’s Venue Family, featuring an easy-to-clean touchscreen, intuitive scanning tools, and a small footprint designed to fit in tight spaces often found in point-of
News | Point-of-Care Ultrasound (POCUS) | March 31, 2021
March 31, 2021 — Driven by pandemic realities and clinical demand for portable and intelligent point-of-care ultrasound...
The Medtronic Harmony Transcatheter Pulmonary Valve (TPV) System. It is first in the world non-surgical heart valve to treat pediatric and adult patients with a native or surgically-repaired right ventricular outflow tract (RVOT) to stop severe pulmonary valve regurgitation caused by congenital heart disease.

The Medtronic Harmony Transcatheter Pulmonary Valve (TPV) System is is designed for patients without a conduit with RVOT malformations who require a correction to their structural malformation early in life and need a minimally invasive option to restore pulmonary valve function.
 

Feature | Structural Heart | March 26, 2021 | By Dave Fornell, Editor
March 26, 2021 — Today, the U.S. Food and Drug Administration (FDA) cleared the Medtronic Harmony Transcatheter...
Virtual tour views of a University of Colorado cath lab during a CTO procedure (top left), the new robotic EP lab at Banner Health (top right), a bi-plane EP/cath combo lab at Baylor Heart Hospital Dallas (bottom left, and an ECMO procedure at Tufts Medical Center cath lab. Photos by Dave Fornell

Virtual tour views of a University of Colorado cath lab during a CTO procedure (top left), the new robotic EP lab at Banner Health (top right), a bi-plane EP/cath combo lab at Baylor Heart Hospital Dallas (bottom left, and an ECMO procedure at Tufts Medical Center cath lab. Photos by Dave Fornell, except the Banner EP lab, by Peter Weiss, M.D.

Feature | March 25, 2021
There is a lot of interest in how other hospitals organize and equip their cardiac cath labs and electrophysiology (EP...
PA pressure-guided heart failure management is fast becoming the standard of care in NYHA Class III patients. The Cordella Pulmonary Artery Pressure Sensor enables clinicians to remotely monitor and proactively adjust therapy and medications remotely without the need for office visits.

PA pressure-guided heart failure management is fast becoming the standard of care in NYHA Class III patients. The Cordella Pulmonary Artery Pressure Sensor enables clinicians to remotely monitor and proactively adjust therapy and medications remotely without the need for office visits.

News | Heart Failure | March 24, 2021
March 24, 2021 — Endotronix Inc., a digital health and medical technology company working on advancements in treating...
Videos | Structural Heart | March 23, 2021
Interview with Scott E. Kasner, M.D., who served as the principle investigator for the Gore Cardioform REDUCE trial,...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Find additional figure in the JACC article.

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Additional figure included in the JACC article.

Feature | Antiplatelet and Anticoagulation Therapies | March 22, 2021 | By Dave Fornell, Editor
A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal...
Boston Scientific's TheraSphere Y-90 Glass Microspheres enable selective internal radiation therapy (SIRT), or radioembolization, for hepatocellular carcinoma. This treats liver cancer with low toxicity using millions of microscopic glass beads containing radioactive yttrium (Y-90), delivered directly to liver tumors via catheter. The result in minimal radiation exposure to surrounding healthy tissue.

Boston Scientific's TheraSphere Y-90 Glass Microspheres enable selective internal radiation therapy (SIRT), or radioembolization, for hepatocellular carcinoma. This treats liver cancer with low toxicity using millions of microscopic glass beads containing radioactive yttrium (Y-90), delivered directly to liver tumors via catheter. The result in minimal radiation exposure to surrounding healthy tissue.

News | Interventional Radiology | March 18, 2021
March 18, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's TheraSphere Y-90 Glass...